news
Once daily multiple sclerosis treatment approved for use in Scotland
The Scottish Medicines Consortium has approved Zeposia® (ozanimod) for use in relapsing remitting multiple sclerosis patients.
List view / Grid view
Scottish Medicines Consortium (SMC)
news
NICE initiates new Innovative Licensing and Access Pathway for medicines
The new pathway developed by NICE for medicines to go from clinical trials to NHS patients is now in action.
news
Scottish Medicines Consortium approves Kymriah® CAR-T therapy
The Kymriah (tisagenlecleucel) treatment has received a positive appraisal from the Scottish Medicines Consortium, after EMA approval last year.
news
SMC accepts restricted use of rivaroxaban for CAD
The SMC has approved a drug, called rivaroxaban, that targets Factor Xa to treat those with coronary artery disease (CAD)...
news
SMC recommends three new medicines for routine use
The Scottish Medicines Consortium has published advice accepting three new medicines for routine use...
news
Nexavar receives final appraisal for primary liver cancer
NICE has released a Final Appraisal Document recommending Nexavar for the treatment of patients with advanced hepatocellular carcinoma...
news
SMC rejects Perjeta (pertuzumab) for NHS use for breast cancer
The Scottish Medicines Consortium (SMC) has made a final decision to turn down Perjeta (pertuzumab) for routine NHS funding for first line use in women whose HER2-positive breast cancer has returned to the breast but is inoperable, or where it has spread to other parts of the body.
news
Scotland approves Ipsen’s cabozantinib to treat kidney cancer
The SMC endorses routine prescribing across NHS Scotland of Ipsen’s cabozantinib, offering a new therapy option to help battle kidney cancer.
news
Scottish Medicines Consortium approves Sanofi prostate cancer drug
14 December 2016 | By Niamh Louise Marriott, Digital Editor
Prostate cancer can become resistant to hormone therapy and continue to grow despite treatment. Jevtana (cabazitaxel) is the only remaining chemotherapy...
news
Scotland speeds ahead to deliver breakthrough immunotherapy to lung cancer patients
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
This recommendation means that patients in Scotland will become the first in the UK to be treated with nivolumab on the NHS...
news
NICE recommends Novartis’ ankylosing spondylitis drug
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE are recommending it as an option to treat adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy...
news
NICE recommends Pfizer’s lung cancer drug after price drop
18 August 2016 | By The National Institute for Health and Care Excellence (NICE)
When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value…
news
SMC ‘U-turn’ offers lifeline to Scottish skin cancer patients
8 August 2016 | By Bristol-Myers Squibb
The SMC initially refused access to nivolumab for Scottish patients, having taken a different view to the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access…
news
SMC accepts five new medicines for use in NHS Scotland
11 July 2016 | By Victoria White, Digital Content Producer
The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib...
news
SMC says ‘no’ to Kalydeco and Orkambi in cystic fibrosis
The Scottish Medicines Consortium (SMC) has rejected Kalydeco (ivacaftor) and Orkambi (lumacaftor-ivacaftor) for the treatment of cystic fibrosis.
